JB Pharma ranks 23 in Indian pharma market

JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app

Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US

Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

The cash consideration for the above acquisition will be Euro 26 million.

Glenmark receives OAI communication from US FDA

The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest

3Brain AG's Accura-3D microchip, enters the market

3D CMOS chip for connecting electroactive tissues and organoids to software

Dozee and Midmark to launch India’s first intelligent connected bed with Remote Patient Monitoring and EWS

The intelligent connected bed is one of the most significant breakthroughs in India’s journey to create a world-class connected healthcare system to deliver quality healthcare to a billion Indians.